<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611750</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002259</org_study_id>
    <nct_id>NCT04611750</nct_id>
  </id_info>
  <brief_title>Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing</brief_title>
  <official_title>Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apnimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no pharmacological intervention for mild symptomatic obstructive sleep&#xD;
      disordered breathing (SDB) in the form of loud habitual snoring, inspiratory flow limitation&#xD;
      (i.e. upper airway resistance syndrome), or mild sleep apnea. Here the investigators study&#xD;
      the effect on SDB of stimulating pharyngeal muscles during sleep with AD036. The key&#xD;
      hypothesis of the study is that AD036 is superior to placebo on self-reported and objective&#xD;
      measures of SDB severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized placebo-controlled 2-period crossover study. Each crossover period will&#xD;
      consist of 14 days of QHS dosing of either AD036 or placebo, with a washout period of 7 days&#xD;
      between each period.&#xD;
&#xD;
      Polysomnography will be performed at screening (baseline) and on the last dosing day of each&#xD;
      of the two crossover dosing period.&#xD;
&#xD;
      The trial will enroll participants until a total of 24 responders are randomized into the&#xD;
      crossover portion of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Snoring Relationship Questionnaire (SRQ)</measure>
    <time_frame>14 days</time_frame>
    <description>Self-reported impact of snoring on relationship and quality of life for patients and bedpartners, 0-20 scale, 0 lowest severity, 20 highest severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Snoring Frequency</measure>
    <time_frame>14 days</time_frame>
    <description>Snoring frequency, % breaths during sleep &gt;100dB by tracheal microphone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Limitation Frequency</measure>
    <time_frame>14 days</time_frame>
    <description>Flow limitation frequency, % breaths during sleep &gt;50% obstructed per airflow shape (Mann D et al ERJ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea-Hypopnea Index</measure>
    <time_frame>14 days</time_frame>
    <description>Apnea-Hypopnea Index, events/hr (hypopneas per 4% desaturation)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Snoring Intensity</measure>
    <time_frame>14 days</time_frame>
    <description>Mean tracheal sound pressure, presented in dB</description>
  </other_outcome>
  <other_outcome>
    <measure>Flow Limitation Severity, %</measure>
    <time_frame>14 days</time_frame>
    <description>Median overnight flow limitation severity (Mann et al ERJ) in %, 0% is maximal flow limitation, 100% is absence of flow limitation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoxic Burden</measure>
    <time_frame>14 days</time_frame>
    <description>Area under curve of pulse oxygen saturation due to respiratory events (Azarbarzin et al EHJ method) in %desaturation.min/hr</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep Apnea Quality of Life Index (Short)</measure>
    <time_frame>14 days</time_frame>
    <description>Sleep-related quality of life on 1-7 scale, 1 is lowest quality of life, 7 is highest quality of life</description>
  </other_outcome>
  <other_outcome>
    <measure>Snoring Self-Evaluation Survey (SSES)</measure>
    <time_frame>14 days</time_frame>
    <description>Snoring-related symptoms and quality of life for the snorer on a 0-16 scale, 0 represents absence of snoring and related symptoms, 16 represents maximal snoring and related symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>Snoring Bedpartner-Evaluation Survey (SBES)</measure>
    <time_frame>14 days</time_frame>
    <description>Snoring-related quality of life for the bedpartneron a 0-16 scale, 0 represents absence of snoring and related symptoms, 16 represents maximal snoring and related symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>14 days</time_frame>
    <description>Sleepiness 0-24 scale, 0 least sleepy, 24 most sleepy</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Analog Scale for Treatment Satisfaction</measure>
    <time_frame>14 days</time_frame>
    <description>Treatment Satisfaction 0-10 scale, 0 most dissatisfied, 5 neutral, 10 most satisfied</description>
  </other_outcome>
  <other_outcome>
    <measure>Participant Global Impression of Severity (PGI-S) of SDB symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Self-reported Symptom Severity 0-4 scale, 0 lowest severity, 4 highest severity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Sleep Disordered Breathing</condition>
  <arm_group>
    <arm_group_label>Active Medication (AD036)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take AD036 QHS for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Medication</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebo QHS for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD036</intervention_name>
    <description>AD036 will be given for 14 days</description>
    <arm_group_label>Active Medication (AD036)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given for 14 days</description>
    <arm_group_label>Placebo Medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria at Enrollment:&#xD;
&#xD;
          -  Between 25 to 70 years of age, inclusive&#xD;
&#xD;
          -  SRQ at screening ≥ 4 (at least mild impact of snoring)&#xD;
&#xD;
          -  ESS at screening ≤ 12 (absence of sleepiness)&#xD;
&#xD;
          -  BMI between 18.5 and 40 kg/m2, inclusive.&#xD;
&#xD;
          -  Use of specified contraceptive methods if appropriate&#xD;
&#xD;
        Inclusion Criteria for First Study Phase (Run-in Period):&#xD;
&#xD;
          -  AHI ≥5-10, or AHI 0-&lt;5 if either:&#xD;
&#xD;
          -  Snoring frequency (100dB snoring for &gt;10% of sleep) by tracheal microphone, or&#xD;
&#xD;
          -  Flow limitation frequency (&gt;50% obstruction for &gt;10% of sleep).&#xD;
&#xD;
          -  PGI-S that improves by at least 1 point during AD036 run-in period&#xD;
&#xD;
        Inclusion Criteria for Randomization:&#xD;
&#xD;
        • PGI-S that improves by at least 1 point during AD036 run-in period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  History of narcolepsy&#xD;
&#xD;
          -  Clinically significant craniofacial malformation&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery&#xD;
             disease or cardiac failure) or hypertension requiring more than 2 medications for&#xD;
             control.&#xD;
&#xD;
          -  Clinically significant neurological disorder, including epilepsy/convulsions.&#xD;
&#xD;
          -  History of schizophrenia, schizoaffective disorder or bipolar disorder&#xD;
&#xD;
          -  History of attempted suicide or suicidal ideation within 1 year prior to screening, or&#xD;
             current suicidal ideation.&#xD;
&#xD;
          -  History of clinically significant constipation, gastric retention, or urinary&#xD;
             retention.&#xD;
&#xD;
          -  Positive screen for drugs of abuse or substance use disorder&#xD;
&#xD;
          -  A significant illness or infection requiring medical treatment in the past 30 days.&#xD;
&#xD;
          -  Clinically significant cognitive dysfunction.&#xD;
&#xD;
          -  Untreated narrow angle glaucoma.&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  History of using oral or nasal devices for the treatment of OSA or snoring; may enroll&#xD;
             as long as the devices are not used during participation in the study.&#xD;
&#xD;
          -  History of using devices to affect participant sleeping position for the treatment of&#xD;
             OSA or snoring, e.g. to discourage supine sleeping position; may enroll as long as the&#xD;
             devices are not used during participation in the study.&#xD;
&#xD;
          -  History of oxygen therapy (last 12 months).&#xD;
&#xD;
          -  Use of medications from the list of disallowed concomitant medications during study&#xD;
             participation.&#xD;
&#xD;
               -  MAOIs or other drugs that affect monoamine concentrations (e.g., rasagiline)&#xD;
                  [MAOIs are contraindicated for use with atomoxetine]&#xD;
&#xD;
               -  Selective Serotonin Reuptake Inhibitors (e.g., paroxetine)&#xD;
&#xD;
               -  Selective Norepinephrine Reuptake Inhibitors (e.g., duloxetine)&#xD;
&#xD;
               -  Norepinephrine Reuptake Inhibitors (e.g., reboxetine)&#xD;
&#xD;
               -  Alpha-1 antagonists (e.g., tamsulosin)&#xD;
&#xD;
               -  Tricyclic antidepressants (e.g., desipramine)&#xD;
&#xD;
               -  Centrally acting antihypertensives (e.g. clonidine, alpha-methyl-DOPA)&#xD;
&#xD;
               -  CYP2D6 inhibitors&#xD;
&#xD;
               -  Strong CYP3A4 inhibitors (e.g., ketoconazole)&#xD;
&#xD;
               -  Benzodiazepines and other anxiolytics or sedatives&#xD;
&#xD;
               -  Nonbenzodiazepine hypnotics&#xD;
&#xD;
               -  Opioids&#xD;
&#xD;
               -  Muscle relaxants&#xD;
&#xD;
               -  Pressor agents&#xD;
&#xD;
               -  Drugs with clinically significant cardiac QT-interval prolonging effects&#xD;
&#xD;
               -  Drugs known to lower seizure threshold (e.g., chloroquine)&#xD;
&#xD;
               -  Amphetamines&#xD;
&#xD;
               -  Antiepileptics&#xD;
&#xD;
               -  Antiemetics&#xD;
&#xD;
               -  Modafinil or armodafinil&#xD;
&#xD;
               -  Beta2 agonists, (e.g., albuterol)&#xD;
&#xD;
               -  Antipsychotics&#xD;
&#xD;
               -  Anticholinergics and anticholinesterase inhibitors, including drugs with&#xD;
                  substantial anticholinergic side effects, (e.g., first generation antihistamines)&#xD;
&#xD;
               -  Sedating antihistamines&#xD;
&#xD;
               -  Pseudoephedrine, phenylephrine, oxymetazoline&#xD;
&#xD;
               -  Nicotine replacement products&#xD;
&#xD;
               -  Most drugs for Parkinson's, Alzheimer's, Huntington's, Amyotrophic Lateral&#xD;
                  Sclerosis, or drugs for other neurodegenerative diseases&#xD;
&#xD;
          -  Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, strong cytochrome P450&#xD;
             2D6 (CYP2D6) inhibitors, or monoamine oxidase inhibitors (MAOI) within 14 days of the&#xD;
             start of treatment, or concomitant with treatment.&#xD;
&#xD;
          -  Use of another investigational agent within 30 days or 5 half-lives prior to dosing,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  &lt;5 hours typical sleep duration.&#xD;
&#xD;
          -  Smoking more than 10 cigarettes or 2 cigars per day.&#xD;
&#xD;
          -  Unwilling to use specified contraception.&#xD;
&#xD;
          -  Unwilling to limit alcohol consumption to no greater than 2 units/day or less for men,&#xD;
             or 1 unit/day for women, not to be consumed within 3 hours of bedtime.&#xD;
&#xD;
          -  Unwilling to limit caffeinated beverage intake (e.g., coffee, cola, tea) to 400 mg/day&#xD;
             or less of caffeine (approximately 4 cups of coffee); caffeine not to be used within 3&#xD;
             hours of bedtime.&#xD;
&#xD;
          -  Any condition that in the investigator's opinion would present an unreasonable risk to&#xD;
             the participant, or which would interfere with their participation in the study or&#xD;
             confound study interpretation.&#xD;
&#xD;
          -  Participant considered by the investigator, for any reason, an unsuitable candidate to&#xD;
             receive AD036 or unable or unlikely to understand or comply with the dosing schedule&#xD;
             or study evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott A Sands, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley A Edwards, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott A Sands, PhD</last_name>
    <phone>617-278-0911</phone>
    <email>sasands@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott A Sands, PhD</last_name>
      <phone>857-928-0341</phone>
      <email>sasands@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash University</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley A Edwards, PhD</last_name>
      <email>bradely.edwards@monash.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Scott Aaron Sands</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Inspiratory flow limitation</keyword>
  <keyword>Snoring</keyword>
  <keyword>Mild Sleep Apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We plan not to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

